(Q37811648)

23 August 2017

title

Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer? (English)

1 reference

23 August 2017

0 references

S Verma

1

1 reference

23 August 2017

M S Ewer

series ordinal

2

1 reference

23 August 2017

language of work or name

1 reference

22 November 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

22

1 reference

23 August 2017

issue

5

1 reference

23 August 2017

page(s)

1011-1018

1 reference

Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ607

Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ607

Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ607

Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ607

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ607

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ607

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ607

Cardiotoxicity profile of trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ607

Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ607

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ607

Cardiovascular toxicity caused by cancer treatment: strategies for early detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ607

Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ607

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ607

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ607

Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ607

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ607

1 reference

23 August 2017

1 reference